Mass cytometry as a platform for the discovery of cellular biomarkers to guide effective rheumatic disease therapy

The development of biomarkers for autoimmune diseases has been hampered by a lack of understanding of disease etiopathogenesis and of the mechanisms underlying the induction and maintenance of inflammation, which involves complex activation dynamics of diverse cell types. The heterogeneous nature an...

Full description

Saved in:
Bibliographic Details
Published in:Arthritis research & therapy 2015-05, Vol.17 (1), p.127-127, Article 127
Main Authors: Nair, Nitya, Mei, Henrik E, Chen, Shih-Yu, Hale, Matthew, Nolan, Garry P, Maecker, Holden T, Genovese, Mark, Fathman, C Garrison, Whiting, Chan C
Format: Article
Language:English
Subjects:
Analysis
Arthritis
Arthritis, Rheumatoid - blood
Arthritis, Rheumatoid - immunology
B cells
Biological markers
Biomarkers - analysis
Care and treatment
Development and progression
Diagnosis
Drug therapy
Female
Humans
Inflammation
Male
Mass Spectrometry - methods
Medical research
Medicine, Experimental
Patients
Review
Rheumatoid factor
Sensitivity and Specificity
Severity of Illness Index
Single-Cell Analysis - methods
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The development of biomarkers for autoimmune diseases has been hampered by a lack of understanding of disease etiopathogenesis and of the mechanisms underlying the induction and maintenance of inflammation, which involves complex activation dynamics of diverse cell types. The heterogeneous nature and suboptimal clinical response to treatment observed in many autoimmune syndromes highlight the need to develop improved strategies to predict patient outcome to therapy and personalize patient care. Mass cytometry, using CyTOF®, is an advanced technology that facilitates multiparametric, phenotypic analysis of immune cells at single-cell resolution. In this review, we outline the capabilities of mass cytometry and illustrate the potential of this technology to enhance the discovery of cellular biomarkers for rheumatoid arthritis, a prototypical autoimmune disease.
ISSN:1478-6354
1478-6362
1478-6354
DOI:10.1186/s13075-015-0644-z